Drug intelligence / Profile preview

OXS-2175

Development stage: Preclinical
Lead developer: GT Biopharma
Modality: Small Molecules
Administration: Intravenous

Overview

OXS-2175 is a **small molecule therapeutic candidate** developed for the treatment of **triple-negative breast cancer (TNBC)**. It has demonstrated the ability to inhibit metastasis in both in vitro and in vivo models of TNBC. The compound is being developed by Oxis Biotech and is positioned as a targeted therapy for an aggressive form of breast cancer that lacks estrogen, progesterone, and HER2 receptors. OXS-2175 is also the payload in an antibody-drug conjugate developed by Oxis Biotech/MultiCell Immunotherapeutics[1][3][9][11][13].

Brand names: OXS-2175OXS2175OXS 2175
Other names: OXS-2175OXS2175OXS 2175

Beyond the preview

Go deeper on OXS-2175.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OXS-2175.

Explore the full profile